Melatonin Decreases Eye Pressure in Normotensive Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03193112|
Recruitment Status : Completed
First Posted : June 20, 2017
Last Update Posted : August 13, 2018
|Condition or disease||Intervention/treatment|
|Depressive Disorder||Drug: Agomelatine 25 MG Oral Tablet|
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||Melatonin Decreases Eye Pressure in Depressive Patients With Normal Intraocular Pressure|
|Actual Study Start Date :||June 16, 2017|
|Actual Primary Completion Date :||October 15, 2017|
|Actual Study Completion Date :||June 15, 2018|
The investigators analyze the intraocular pressure changes on patients who have been using Agomelatine for their primary depressive disorder. For the treatment of depression, patients will have been started routinely Agomelatine tablet of 25 mg orally. The investigators measure the eye pressure for one months in those patients receiving standard depression treatment.
Drug: Agomelatine 25 MG Oral Tablet
We will treat our patients with Agomelatine tablet of 25 mg.
- Intraocular pressure [ Time Frame: One month ]mmHg
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03193112
|Kahramanmaras Sutcuimam University Ophthalmology Department|
|Kahramanmaraş, Turkey, 46050|
|Principal Investigator:||Gokhan Ozdemir, MD||KSU|